Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009824 | 1.00 | CA1 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL1009355 | 1.00 | CA1 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL3823617 | 1.00 | CA1 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL7637140 | 0.82 | CES2 (0.59) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL27860116 | 0.80 | CES2 (0.57) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL28855975 | 0.79 | CA1 (0.55) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL757101 | 0.79 | CES2 (0.61) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL4949476 | 0.78 | CES2 (0.62) | CES2CES1PARP1KMT2AMEN1 | |
| SCHEMBL16321528 | 0.78 | CA1 (0.49) | CA1CA2CES2CES1PARP10 | |
| SCHEMBL29733566 | 0.78 | CA1 (0.49) | CA1CA2CES2CES1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| CN-118994172-A | Preparation method of poncirtinib phosphate | 广州科锐特生物科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024184926-A1 | PROCESS FOR PREPARATION OF CHIRAL RUXOLITINIB AND SALTS THEREOF | AARTI PHARMALABS LIMITED (IN) | 2024-09-12 | — | — | WO | claimed |
| CN-117222623-A | Acid addition salts of (S) -3- (2, 5-dimethoxy-4- (trifluoromethyl) phenyl) piperidine and (S) -3- (2-methoxy-5- (methylthio) -4- (trifluoromethyl) phenyl) piperidine, specific polymorphs thereof and processes for preparing the same | 罗弗拉有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116854642-A | Preparation method of (S) -2-piperazine acetonitrile and hydrochloride thereof | 重庆博腾制药科技股份有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116135866-A | Bridged carboxylic acid-containing difunctional phosphine ligand, preparation method and application thereof | 中山大学 | 2023-05-19 | — | — | CN | claimed |
| US-11578041-B2 | Crystals of hydroxychloroquine sulfate | GENOVATE BIOTECHNOLOGY CO. LTD. (TW) | 2023-02-14 | — | — | US | claimed |
| CN-108884081-B | Process for separating enantiomers of piperazine derivatives | 阿森纽荣股份公司 | 2022-11-01 | — | — | CN | claimed |
| WO-2008146249-A1 | PROCESSES FOR THE PREPARATION OF CLOPIDOGREL | WOCKHARDT RESEARCH CENTRE (IN) | 2008-12-04 | — | — | WO | claimed |
| EP-1984368-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AN OPTICALLY ACTIVE 5H-PYRROLO [3,4-B]PYRAZINE DERIVATIVE | Glenmark Pharmaceuticals Limited (IN) | 2008-10-29 | — | — | EP | claimed |
| WO-2008107911-A2 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2008-09-12 | — | — | WO | claimed |
| WO-2008068569-A2 | PROCESSES FOR THE PREPARATION OF CLOPIDOGREL HYDROCHLORIDE | WOCKHARDT RESEARCH CENTRE (IN) | 2008-06-12 | — | — | WO | claimed |
| WO-2007083188-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AN OPTICALLY ACTIVE 5H-PYRROLO [3,4-B] PYRAZINE DERIVATIVE | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-07-26 | — | — | WO | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| WO-2004010985-A1 | PERSONAL DEODORANT | BETTS JOHN ADRIAN (GB) | 2004-02-05 | — | — | WO | claimed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | CA1 1383/4885CA2 349/4885CES2 3211/4885 |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | CA1 2106/4885CA2 2307/4885CES2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.